| Literature DB >> 23148106 |
Cathrine Hoyo1, Michael B Cook, Farin Kamangar, Neal D Freedman, David C Whiteman, Leslie Bernstein, Linda M Brown, Harvey A Risch, Weimin Ye, Linda Sharp, Anna H Wu, Mary H Ward, Alan G Casson, Liam J Murray, Douglas A Corley, Olof Nyrén, Nirmala Pandeya, Thomas L Vaughan, Wong-Ho Chow, Marilie D Gammon.
Abstract
BACKGROUND: Previous studies suggest an association between obesity and oesophageal (OA) and oesophagogastric junction adenocarcinomas (OGJA). However, these studies have been limited in their ability to assess whether the effects of obesity vary by gender or by the presence of gastro-oesophageal reflux (GERD) symptoms.Entities:
Mesh:
Year: 2012 PMID: 23148106 PMCID: PMC3535758 DOI: 10.1093/ije/dys176
Source DB: PubMed Journal: Int J Epidemiol ISSN: 0300-5771 Impact factor: 7.196
BEACON studies available for analysis of body mass index and adenocarcinomas of the oesophagus and oesophagogastric junction
| Name | Country of Study | Period of Recruitment | Cases | Controls | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| OA ( | OGJA ( | AA ( | Age [mean (SD)] | Male (%) | BMI [mean (SD)] | Age [mean (SD)] | Male (%) | BMI [mean (SD)] | ||||
| Australian Cancer Study | Australia | 2001–05 | 344 | 403 | 747 | 63.5 (9.7) | 88.5 | 28.7 (5.0) | 1447 | 60.5 (11.7) | 65.8 | 26.9 (4.6) |
| Nova Scotia Barrett Esophagus Study | Canada | 2001–03 | 55 | 55 | 64.2 (9.7) | 89.5 | 27.5 (5.6) | 99 | 54.7 (13.7) | 64.7 | 28.9 (5.9) | |
| Factors Influencing the Barrett’s Adenocarcinoma Relationship Study | Ireland | 2002–04 | 130 | 92 | 222 | 64.2 (11.1) | 85.2 | 28.6 (4.8) | 259 | 63.0 (12.8) | 84.6 | 27.0 (3.9) |
| Swedish Esophageal Cancer Study | Sweden | 1995–97 | 189 | 262 | 451 | 65.3 (9.9) | 86.0 | 25.6 (3.9) | 816 | 66.0 (10.0) | 82.8 | 23.9 (2.8) |
| United Kingdom Study of Esophageal Cancer in Women | United Kingdom | 1993–96 | 72 | 72 | 65.3 (8.7) | 0.0 | 29.8 (6.9) | 72 | 65.9 (8.8) | 0.0 | 26.9 (4.8) | |
| Kaiser Permanente Multiphasic Health Checkup Study | United States | 1964–73 | 86 | 85 | 171 | 46.2 (11.2) | 80.6 | 26.2 (3.6) | 2021 | 47.5 (11.0) | 74.6 | 25.2 (3.7) |
| Larynx/Esophagus/Oral Cavity Study | United States | 1983–90 | 129 | 154 | 283 | 61.1 (9.3) | 89.6 | 26.5 (4.4) | 694 | 59.8 (10.0) | 69.9 | 25.9 (4.0) |
| Los Angeles Multi-ethnic Study | United States | 1992–97 | 168 | 205 | 373 | 60.9 (9.8) | 86.7 | 27.0 (5.2) | 834 | 58.7 (11.5) | 73.7 | 25.8 (4.4) |
| Nebraska Health Study II | United States | 1988–93 | 123 | 44 | 167 | 68.3 (12.4) | 86.6 | 26.4 (3.7) | 489 | 68.3 (17.6) | 56.6 | 25.2 (4.5) |
| NIH-AARP Study | United States | 1995–96 | 366 | 296 | 662 | 63.7 (5.0) | 90.9 | 28.2 (4.8) | 3083 | 62.1 (5.3) | 60.2 | 27.0 (4.7) |
| Population Health Study | United States | 1986–89 | 58 | 113 | 171 | 62.5 (9.6) | 100.0 | 26.7 (3.8) | 722 | 61.3 (11.0) | 100.0 | 25.2 (3.2) |
| US Multi-Center Study | United States | 1993–95 | 277 | 246 | 523 | 63.7 (10.9) | 84.5 | 26.1 (4.2) | 623 | 62.8 (10.7) | 79.9 | 24.9 (3.4) |
| Total | ||||||||||||
Case–control study.
bCohort study with a nested case–control set selected for BEACON.
OA = oesophageal adenocarcinoma; OGJA = oesophagogastric junction adenocarcinoma; AA = all adenocarcinomas (OA and OGJA); BMI = body mass index; SD = standard deviation.
Adjusted summary odds ratios and 95% confidence intervals for the association between body mass index and adenocarcinomas of the oesophagus and oesophagogastric junction among all subjects (men and women combined)
| OA | OGJA | All adenocarcinomas | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| BMI (kg/m2) | Controls ( | Cases ( | OR | 95% CI | Controls ( | Cases ( | OR | 95% CI | Controls ( | Cases ( | OR | 95% CI | |||||||||
| <25.0 | 4744 | 577 | Referent | 4686 | 663 | Referent | 4777 | 1240 | Referent | ||||||||||||
| 25.0–29.9 | 4232 | 862 | 1.54 | 1.26–1.88 | 55 | 12 | 4147 | 742 | 1.28 | 1.13–1.45 | 0 | 10 | 4232 | 1604 | 1.41 | 1.24–1.60 | 37 | 12 | |||
| 30.0–34.9 | 1109 | 331 | 2.39 | 1.86–3.06 | 42 | 12 | 1081 | 304 | 2.08 | 1.75–2.47 | 0 | 10 | 1109 | 635 | 2.23 | 1.83–2.71 | 41 | 12 | |||
| 35.0–39.9 | 273 | 86 | 2.79 | 1.89–4.12 | 23 | 11 | 266 | 85 | 2.36 | 1.75–3.17 | 0 | 9 | 273 | 171 | 2.40 | 1.89–3.04 | 0 | 11 | |||
| ≥40 | 94 | 41 | 4.76 | 2.96–7.66 | 0 | 9 | 91 | 28 | 3.07 | 1.89–4.99 | 0 | 8 | 99 | 69 | 3.65 | 2.50–5.34 | 0 | 10 | |||
| Continuous | 10 481 | 1897 | 1.09 | 1.06–1.12 | 76 | 12 | 10 295 | 1822 | 1.07 | 1.05–1.09 | 54 | 10 | 10 481 | 3719 | 1.08 | 1.06–1.10 | 75 | 12 | |||
Results were adjusted for age (categorical: <50, 50–59, 60–69, ≥70 years), gender, pack-years of smoking (categorical: <15, 15 to <30, 30 to <45, ≥45), education (study-specific) and other study-specific adjustment variables (e.g. study centre, where applicable). Summary odds ratios and 95% confidence intervals were obtained from random-effects models. All 12 studies were included for analysis unless otherwise specified.
I estimates variability in results across studies.
OA = oesophageal adenocarcinoma; OGJA = oesophagogastric junction adenocarcinoma; AA = all adenocarcinomas (OA and OGJA); BMI = body mass index; OR = odds ratio; N = number of studies in the analysis.
Adjusted odds ratios and 95% confidence intervals for the association between body mass index and risk of oesophageal adenocarcinoma, oesophagogastric junction adenocarcinoma and all adenocarcinomas, stratified by heartburn and gastro-oesophageal reflux
| No GERD | GERD | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| BMI (kg/m2) | Controls ( | Cases ( | OR | 95% CI | Controls ( | Cases ( | OR | 95% CI | ||
| Oesophageal adenocarcinoma | ||||||||||
| <25.0 | 614 | 94 | Referent | 705 | 180 | Referent | ||||
| 25.0–29.9 | 532 | 95 | 1.12 | 0.80–1.58 | 0 | 739 | 282 | 1.48 | 1.07–2.05 | 40 |
| 30.0–34.9 | 136 | 37 | 1.85 | 0.91–3.73 | 48 | 224 | 129 | 2.21 | 1.44–3.39 | 37 |
| 35.0–39.9 | 47 | 15 | 2.08 | 1.00–4.30 | 0 | 62 | 36 | 2.95 | 1.15–7.59 | 49 |
| ≥40 | 10 | 4 | 6.45 | 1.60–25.99 | 100 | 20 | 18 | 5.84 | 2.72–12.55 | 0 |
| Continuous | 1341 | 246 | 1.07 | 1.03–1.11 | 0 | 1750 | 645 | 1.08 | 1.03–1.14 | 71 |
| Oesophagogastric junctional adenocarcinoma | ||||||||||
| <25.0 | 614 | 128 | Referent | 705 | 172 | Referent | ||||
| 25.0–29.9 | 532 | 136 | 1.22 | 0.77–1.95 | 56 | 739 | 239 | 1.16 | 0.87–1.56 | 24 |
| 30.0–34.9 | 136 | 54 | 2.08 | 1.36–3.19 | 0 | 224 | 116 | 1.91 | 1.4–2.6 | 0 |
| 35.0–39.9 | 47 | 14 | 1.49 | 0.74–2.98 | 0 | 62 | 40 | 3.65 | 1.58–8.46 | 50 |
| ≥40 | 12 | 4 | 3.20 | 0.89–11.52 | 0 | 20 | 11 | 2.64 | 1.16–5.99 | 0 |
| Continuous | 1341 | 337 | 1.06 | 1.03–1.09 | 0 | 1750 | 578 | 1.07 | 1.04–1.09 | 0 |
| All adenocarcinomas | ||||||||||
| <25.0 | 614 | 222 | Referent | 705 | 352 | Referent | ||||
| 25.0–29.9 | 532 | 231 | 1.20 | 0.92–1.58 | 17 | 739 | 521 | 1.33 | 1.02–1.74 | 44 |
| 30.0–34.9 | 136 | 91 | 1.88 | 1.32–2.67 | 0 | 224 | 245 | 2.09 | 1.58–2.77 | 13 |
| 35.0–39.9 | 47 | 29 | 1.68 | 0.97–2.93 | 0 | 62 | 76 | 2.98 | 1.5–5.93 | 45 |
| ≥40 | 12 | 8 | 3.74 | 1.33–10.54 | 0 | 20 | 29 | 4.23 | 2.21–8.09 | 0 |
| Continuous | 1341 | 583 | 1.06 | 1.04–1.09 | 0 | 1750 | 1223 | 1.08 | 1.05–1.11 | 54 |
Results were adjusted for age (categorical: <50, 50–59, 60–69, ≥70 years), gender, pack-years of smoking (categorical: <15, 15 to <30, 30 to <45, ≥45), education (study-specific) and other study-specific adjustment variables (e.g. study centre, where applicable). Summary odds ratios and 95% confidence intervals were obtained from random-effects meta-analytic models. The four studies that had heartburn and reflux information available were included in these analyses.
aOnly one of the four studies with heartburn and reflux data was able to contribute a study-specific odds ratio to this summary estimate.
bOnly two of the four studies with heartburn and reflux data were able to contribute a study-specific odds ratio to this summary estimate.
Adjusted summary odds ratios and 95% confidence intervals for the association between body mass index and adenocarcinomas of the oesophagogastric junction stratified by gender
| OA | OGJA | All adenocarcinomas | |||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| BMI (kg/m2) | Controls ( | Cases (n) | OR | 95% CI | Controls ( | Cases ( | OR | 95% CI | Controls ( | Cases ( | OR | 95% CI | |||
| Males | |||||||||||||||
| <25.0 | 3171 | 477 | Referent | 3157 | 535 | Referent | 3171 | 1012 | Referent | ||||||
| 25.0–29.9 | 3310 | 779 | 1.63 | 1.32–2.00 | 51 | 3274 | 675 | 1.36 | 1.19–1.55 | 0 | 3310 | 1454 | 1.49 | 1.29–1.71 | 38 |
| 30.0–34.9 | 743 | 280 | 2.47 | 1.94–3.13 | 26 | 733 | 268 | 2.24 | 1.85–2.71 | 0 | 743 | 548 | 2.38 | 1.95–2.91 | 32 |
| 35.0–39.9 | 150 | 69 | 2.87 | 1.89–4.36 | 17 | 149 | 68 | 2.50 | 1.78–3.53 | 0 | 150 | 137 | 2.58 | 1.94–3.43 | 2 |
| ≥40 | 33 | 22 | 4.47 | 2.42–8.26 | 0 | 33 | 16 | 3.16 | 1.63–6.11 | 0 | 35 | 38 | 3.49 | 2.09–5.84 | 0 |
| Continuous | 5588 | 1306 | 1.09 | 1.06–1.13 | 76 | 5525 | 1320 | 1.08 | 1.06–1.11 | 51 | 5588 | 2626 | 1.09 | 1.06–1.11 | 75 |
| Females | |||||||||||||||
| <25.0 | 1369 | 94 | Referent | 1529 | 128 | Referent | 1567 | 227 | Referent | ||||||
| 25.0–29.9 | 794 | 80 | 1.24 | 0.67–2.29 | 56 | 873 | 67 | 1.04 | 0.67–1.61 | 26 | 910 | 147 | 1.06 | 0.81–1.38 | 0 |
| 30.0–34.9 | 331 | 49 | 2.66 | 1.59–4.46 | 17 | 296 | 36 | 1.71 | 1.06–2.77 | 0 | 362 | 85 | 1.74 | 1.24–2.43 | 0 |
| 35.0–39.9 | 110 | 11 | 1.38 | 0.57–3.35 | 0 | 114 | 15 | 1.80 | 0.92–3.52 | 0 | 115 | 29 | 1.83 | 1.06–3.15 | 0 |
| ≥40 | 46 | 13 | 5.88 | 2.28–15.1 | 0 | 51 | 9 | 3.08 | 1.25–7.56 | 0 | 57 | 23 | 3.55 | 1.87–6.75 | 0 |
| Continuous | 1522 | 228 | 1.07 | 1.04–1.10 | 13 | 1786 | 220 | 1.04 | 1.01–1.07 | 0 | 1878 | 457 | 1.05 | 1.03–1.07 | 0 |
Results were adjusted for age (categorical: <50, 50–59, 60–69, ≥70 years), pack-years of smoking (categorical: <15, 15 to <30, 30 to <45, ≥45), education (study-specific) and other study-specific adjustment variables (e.g. study centre, where applicable). Summary odds ratios and 95% confidence intervals were obtained from random-effects models.
I estimates variability in results across studies.
OA = oesophageal adenocarcinoma; OGJA = oesophagogastric junction adenocarcinoma; BMI = body mass index; OR = odds ratio.
Figure 1Restricted cubic spline models of the relationship between body mass index and adenocarcinomas of the oesophagus and oesophagogastric junction. (a) Oesophageal adenocarcinoma in men. (b) Oesophageal adenocarcinoma in women. (c) Oesophagogastric junction adenocarcinoma in men. (d) Oesophagogastric junction adenocarcinoma in women. Plots are restricted to body mass indexes 18.5–45 and odds ratios 0.25–5 for clarity and consistency
Interaction statistics for departure from additivity
| Departure from additivity | |||
|---|---|---|---|
| Variables tested for interaction with body mass index | ICR (95% CI) (null hypothesis = 0) | AP (95% CI) (null hypothesis = 0) | S (95%CI) (null hypothesis = 1) |
| OA vs controls | |||
| Cigarette smoking | 0.22 (−0.30, 0.73) | 0.07 (−0.09, 0.22) | 1.11 (0.87, 1.40) |
| Alcohol | 0.05 (−0.30, 0.40) | 0.04 (−0.25, 0.34) | 1.31 (0.12, 13.74) |
| | 0.06 (−0.77, 0.89) | 0.03 (−0.42, 0.49) | 1.08 (0.37, 3.20) |
| Heartburn | 0.44 (−0.16, 1.04) | 0.18 (−0.04, 0.39) | 1.42 (0.89, 2.26) |
| Reflux | 0.14 (−0.31, 0.58) | 0.08 (−0.16, 0.32) | 1.20 (0.64, 2.28) |
| Heartburn or refluxa | |||
| OGJA vs controls | |||
| Cigarette smoking | 0.25 (−0.28, 0.78) | 0.08 (−0.08, 0.23) | 1.12 (0.88, 1.44) |
| Alcohol | 0.02 (−0.30, 0.33) | 0.02 (−0.36, 0.40) | 0.90 (0.16, 4.97) |
| | −0.37 (−0.97, 0.22) | −0.44 (−1.18, 0.30) | |
| Heartburn | 0.05 (−0.34, 0.45) | 0.04 (−0.22, 0.29) | 1.12 (0.48, 2.58) |
| Reflux | 0.29 (−0.01, 0.58) | 0.25 (0.00, 0.50) | |
| Heartburn or reflux | 0.30 (−0.01, 0.60) | 0.20 (0.00, 0.40) | 2.51 (0.42, 14.98) |
AP = attributable proportion due to interaction; ICR = interaction contrast ratio; OR = odds ratio; S = synergy index.
aThe excess risk attributable to the synergistic interaction of heartburn or reflux and high BMI ICR, attributable proportion (AP) of OA.